Epoch Investment Partners Inc. cut its holdings in shares of Revvity, Inc. (NYSE:RVTY – Free Report) by 12.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,021 shares of the company’s stock after selling 291 shares during the period. Epoch Investment Partners Inc.’s holdings in Revvity were worth $212,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of the business. Czech National Bank boosted its position in shares of Revvity by 0.5% during the first quarter. Czech National Bank now owns 21,713 shares of the company’s stock valued at $2,280,000 after buying an additional 99 shares during the last quarter. Inspire Investing LLC boosted its position in shares of Revvity by 2.9% during the first quarter. Inspire Investing LLC now owns 4,190 shares of the company’s stock valued at $440,000 after buying an additional 117 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its position in shares of Revvity by 3.6% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,899 shares of the company’s stock valued at $409,000 after buying an additional 135 shares during the last quarter. Empirical Finance LLC boosted its position in shares of Revvity by 3.7% during the first quarter. Empirical Finance LLC now owns 4,225 shares of the company’s stock valued at $444,000 after buying an additional 151 shares during the last quarter. Finally, Byrne Asset Management LLC boosted its position in shares of Revvity by 1.6% during the first quarter. Byrne Asset Management LLC now owns 10,215 shares of the company’s stock valued at $1,073,000 after buying an additional 165 shares during the last quarter. 86.65% of the stock is owned by hedge funds and other institutional investors.
Revvity Price Performance
RVTY stock traded up $2.34 during trading on Friday, reaching $115.15. The company’s stock had a trading volume of 1,384,132 shares, compared to its average volume of 833,285. The company’s fifty day moving average is $108.82 and its 200-day moving average is $106.50. Revvity, Inc. has a 1 year low of $79.50 and a 1 year high of $131.96. The company has a market capitalization of $14.21 billion, a P/E ratio of 95.17, a price-to-earnings-growth ratio of 3.00 and a beta of 1.05. The company has a quick ratio of 1.92, a current ratio of 2.23 and a debt-to-equity ratio of 0.40.
Revvity Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, November 8th. Investors of record on Friday, October 18th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Friday, October 18th. This represents a $0.28 dividend on an annualized basis and a yield of 0.24%. Revvity’s dividend payout ratio is presently 23.14%.
Insider Buying and Selling
In related news, insider Joel S. Goldberg sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $110.46, for a total value of $441,840.00. Following the transaction, the insider now directly owns 36,900 shares of the company’s stock, valued at approximately $4,075,974. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.60% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
Several equities research analysts recently commented on RVTY shares. SVB Leerink started coverage on Revvity in a research report on Monday, July 8th. They set an “outperform” rating and a $125.00 price objective on the stock. Barclays dropped their target price on Revvity from $116.00 to $115.00 and set an “equal weight” rating on the stock in a research report on Friday, June 28th. Leerink Partnrs raised Revvity to a “strong-buy” rating in a research report on Monday, July 8th. Robert W. Baird raised their price objective on shares of Revvity from $126.00 to $127.00 and gave the stock an “outperform” rating in a report on Tuesday, April 30th. Finally, Jefferies Financial Group began coverage on shares of Revvity in a report on Monday, June 3rd. They set a “hold” rating and a $115.00 target price for the company. Seven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $119.14.
View Our Latest Stock Report on Revvity
About Revvity
Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Read More
- Five stocks we like better than Revvity
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- Is Crypto Cool Again? What Stocks You Should Be Watching
- How to Capture the Benefits of Dividend Increases
- Why Call Options Volume for These 2 Stocks Spiked Together
- The 3 Best Fintech Stocks to Buy Now
- MarketBeat Week in Review – 7/22 – 7/26
Want to see what other hedge funds are holding RVTY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revvity, Inc. (NYSE:RVTY – Free Report).
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.